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Abstract
Background: Fluoroquinolones are among the most commonly prescribed antimicrobials and are an important
risk factor for colonization and infection with fluoroquinolone-resistant gram-negative bacilli and for Clostridium
difficile infection (CDI). In this study, our aim was to determine current patterns of inappropriate fluoroquinolone
prescribing among hospitalized patients, and to test the hypothesis that longer than necessary treatment durations
account for a significant proportion of unnecessary fluoroquinolone use.
Methods: We conducted a 6-week prospective, observational study to determine the frequency of, reasons for,
and adverse effects associated with unnecessary fluoroquinolone use in a tertiary-care academic medical center.
For randomly-selected adult inpatients receiving fluoroquinolones, therapy was determined to be necessary or
unnecessary based on published guidelines or standard principles of infectious diseases. Adverse effects were
determined based on chart review 6 weeks after completion of therapy.
Results: Of 1,773 days of fluoroquinolone therapy, 690 (39%) were deemed unnecessary. The most common
reasons for unnecessary therapy included administration of antimicrobials for non-infectious or non-bacterial
syndromes (292 days-of-therapy) and administration of antimicrobials for longer than necessary durations (234
days-of-therapy). The most common syndrome associated with unnecessary therapy was urinary tract infection or
asymptomatic bacteriuria (30% of all unnecessary days-of-therapy). Twenty-seven percent (60/227) of regimens
were associated with adverse effects possibly attributable to therapy, including gastrointestinal adverse effects (14%
of regimens), colonization by resistant pathogens (8% of regimens), and CDI (4% of regimens).
Conclusions: In our institution, 39% of all days of fluoroquinolone therapy were unnecessary. Interventions that
focus on improving adherence with current guidelines for duration of antimicrobial therapy and for management
of urinary syndromes could significantly reduce overuse of fluoroquinolones.
Background
Fluoroquinolones are among the most commonly pre-
scribed antibiotics in outpatient and inpatient settings in
the United States [1]. Increases in the use of fluoroqui-
nolones in recent years have coincided with steady
increases in the incidence of fluoroquinolone-resistance
among gram-negative bacilli in intensive care units [2].
In addition, fluoroquinolone exposure has been asso-
ciated with colonization and infection with other health-
care-associated pathogens, including methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
enterococci (VRE), and Clostridium difficile [3-5].
Reducing the use of fluoroquinolones may be an effec-
tive strategy to limit the dissemination of these patho-
gens [6,7]. For example, a restriction program that
resulted in a 66% reduction in use of fluoroquinolones
was associated with control of an outbreak of C. difficile
infection (CDI) associated with fluoroquinolone-resistant
North American pulsed-field gel electrophoresis type 1
(NAP1) strains [7].
Several studies have demonstrated that fluoroquino-
lones are often used inappropriately [8-12]. Lautenbach
et al. [8] found that 81% of fluoroquinolone prescrip-
tions in two academic emergency departments were
inappropriate based on institutional guidelines. In a
French teaching hospital, Mean et al. [9] found that 51%
of fluoroquinolone regimens were innappropriate based
on local prescription guidelines. In a tertiary care
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antimicrobial therapy were unnecessary, with ciprofloxa-
cin being the agent most often prescribed unnecessarily
[11]. Other small studies have reported frequent misuse
of ciprofloxacin and levofloxacin in U.S. hospitals
[11,12]. In order to develop effective stewardship inter-
ventions, there is a need for additional data on current
patterns of inappropriate fluoroquinolone prescribing
among hospitalized patients. Therefore, we performed a
prospective study to determine the frequency of, reasons
for, and adverse effects of unnecessary fluoroquinolone
use in a tertiary care medical center. We hypothesized
that longer than necessary treatment durations would
account for a significant proportion of unnecessary
fluoroquinolone use.
Methods
Setting
MetroHealth Medical Center is a 650-bed tertiary care
hospital in Cleveland, Ohio. The hospital has training
programs for residents in internal medicine, family prac-
tice, obstetrics and gynecology, and several surgical sub-
specialties. The fluoroquinolones on formulary are
ciprofloxacin and moxifloxacin. Fluoroquinolones are
routinely prescribed for prophylaxis prior to invasive
urologic procedures, but not for prophylaxis of other
procedures or conditions. The hospital does not have a
formal antimicrobial stewardship program and there are
no restrictions or specific guidelines on fluoroquinolone
use. However, pharmacists are assigned to some hospital
wards to make antimicrobial recommendations regard-
ing appropriate dosing, potential medication interac-
tions, and potential allergic reactions. Pharmaceutical
company representative are allowed to sponsor educa-
tional programs for trainees in the hospital and provide
promotional materials, but are not allowed to give pre-
sentations related to their products. During the year of
the study, the percent susceptibilities of Escherichia coli,
Pseudomonas aeruginosa,a n dKlebsiella pneumoniae to
ciprofloxacin were 84%, 75%, and 95%, respectively. The
percent susceptibility of E. coli to trimethoprim-sulfa-
methoxazole was 81%.
Study Design
We prospectively examined the necessity of oral and
parenteral fluoroquinolones administered to adult inpa-
tients during a 6-week period in May and June 2009.
T h es t u d yd e s i g nw a sb a s e do nap r e v i o u ss t u d yo f
unnecessary use of antimicrobials in our facility [11].
Patients receiving new prescriptions for fluoroquino-
lones were identified through daily review of pharmacy
records. If 10 or less patients received new prescriptions
for fluoroquinolones on a given day, all patients were
enrolled. If more than 10 patients received new
prescriptions, 10 patients were randomly selected to be
included in the study using a random number generator.
Patients were allowed to be enrolled more than once if
they received a second fluoroquinolone regimen at least
4 weeks after completion of the initial regimen. The
study wards included 6 medical wards, 3 surgical wards,
3 intensive care units, 1 rehabilitation ward, 1 subacute
skilled nursing ward, 1 psychiatric ward, 1 obstetric/
gynecologic ward, and the emergency department. Infor-
mation regarding demographics, admitting service and
ward, indication for antimicrobial therapy (prophylaxis
versus treatment), concurrent antimicrobials, clinical
syndrome being treated, laboratory data, vital signs, radi-
ological tests, and complications of therapy was obtained
through medical record review and recorded on a stan-
dardized data collection form. Patients were followed
through their entire hospital course, including transfers
between hospital units.
Patients’ medical records were reviewed at least once
during the course of antimicrobial therapy and again six
weeks after completion of therapy to assess whether
possible complications or adverse effects of unnecessary
therapy occurred. The frequency of adverse effects was
calculated for all unnecessary fluoroquinolone regimens
and for those unnecessary regimens in which fluoroqui-
nolones were administered as monotherapy. Coloniza-
tion or infection with a resistant pathogen (i.e.,
fluoroquinolone-resistant gram-negative bacillus, vanco-
mycin-resistant enterococci [VRE], or methicillin-resis-
tant Staphylococcus aureus [MRSA]) was considered a
possible complication of therapy only if the patient did
not have a history of colonization or infection with
these organisms prior to the start of fluoroquinolone
therapy; no routine surveillance for VRE or MRSA was
conducted during the study period.
Infectious diseases specialists (M.T.H. and C.J.D.)
determined whether the fluoroquinolone regimens were
necessary or unnecessary. A fluoroquinolone regimen
was defined as unnecessary if no antimicrobial therapy
was indicated for the condition being treated or if the
fluoroquinolone component of a regimen was not indi-
cated. If the fluoroquinolone was determined to be
necessary, additional assessments were made regarding
whether part of the fluoroquinolone regimen was unne-
cessary. Part of the fluoroquinolone regimen was consid-
ered unnecessary if the duration of therapy was longer
than recommended, the fluoroquinolone provided
redundant antimicrobial coverage in the absence of an
indication for combination therapy, the fluoroquinolone
provided inadequate coverage of expected or documen-
ted pathogens, and if the fluoroquinolone was continued
despite negative evaluation for infectious syndromes
and/or a noninfectious condition was demonstrated to
be responsible for the clinical syndrome.
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fluoroquinolones was based on standard practice guide-
lines for management of infectious diseases developed
and/or endorsed by the Infectious Diseases Society of
America [13]. For example, current guidelines for
asymptomatic bacteriuria recommend treatment only for
pregnant women or individuals undergoing invasive uro-
logic procedures [14]; to diagnose asymptomatic bacter-
iuria we required documentation that urinary symptoms
were not present. If standard practice guidelines were
not available, diagnostic and treatment recommenda-
tions from a current textbook of infectious diseases
were used [14]. Hospital-acquired infections were
defined by Centers for Disease Control and Prevention
criteria [15]. If fluoroquinolones were considered neces-
sary, we determined if there was an equally effective
alternative agent that could have been prescribed. The
rationale was to provide an estimate of how much fluor-
oquinolone use could be safely reduced if a hospital
chose to implement a program of complete restriction
of fluoroquinolones in an effort to control C. difficile or
resistant gram-negative bacilli.
To determine the contribution of fluoroquinolones to
total antibiotic use in the hospital, we examined phar-
macy records for all antibiotics prescribed during the
s t u d yp e r i o d .T h ep r o p o r t i o n of total antibiotic use
(days of therapy) that was made up of fluoroquinolone
use was calculated. In addition, for the year of the study,
we estimated the costs of all fluoroquinolone therapy
and of the unnecessary fluoroquinolone therapy based
on average wholesale prices and on acquisition costs for
the hospital.
Statistical analysis
Data were analyzed with the use of SPSS statistical soft-
ware version 10.0 (SPSS Inc., Chicago, IL) and STATA
9.1 (StataCorp, College Station, TX). Bivariate analyses
were performed to compare necessary and unnecessary
treatment regimens. Continuous data were analyzed
using student’su n p a i r e dt-tests. Categorical data were
assessed using Pearson Chi-square test or Fisher’se x a c t
test. The hospital’s institutional review board approved
the study protocol and waived the requirement for
informed consent due to the observational nature of the
study.
Results
Two hundred twenty-six study subjects received 227
fluoroquinolone regimens during the study period (1
patient was prescribed 2 fluoroquinolone regimens). Fig-
ure 1 summarizes the findings regarding the necessity of
fluoroquinolone regimens. Of the 227 fluoroquinolone
regimens, 70 (31%) were deemed unnecessary. These
unnecessary regimens resulted in 391 days of
fluoroquinolone therapy, which accounted for 22% of
the total days of fluoroquinolone therapy. Analysis of
the 157 necessary fluoroquinolone regimens revealed
that an additional 299 days of therapy were unnecessary.
Overall, 690 of the 1773 (39%) days of fluoroquinolone
therapy were deemed unnecessary and 120 of the 226
(53%) study patients received at least one day of unne-
cessary fluoroquinolone therapy.
Table 1 provides a comparison of the characteristics of
patients receiving necessary versus unnecessary fluoro-
quinolone regimens. Patients receiving unnecessary
fluoroquinolone regimens had an older median age than
patients receiving necessary regimens (P = 0.002); how-
ever, there were no significant differences in regards to
sex, previous hospitalizations, previous antibiotics, long-
term care residence, or comorbidities. A majority of the
fluoroquinolone regimens were prescribed on the medi-
cal wards or in the emergency department. Only the
family practice and rehabilitation medicine wards pre-
scribed significantly more unnecessary than necessary
regimens (P ≤ 0.028).
Table 2 summarizes the reasons for the unnecessary
days of fluoroquinolone therapy. The most common
reason for entirely unnecessary fluoroquinolone regi-
mens was treatment of non-infectious or non-bacterial
syndromes or of colonization or contamination (292
days of therapy), with asymptomatic bacteriuria account-
ing for 158 of the unnecessary days. For the necessary
regimens, the most common reason for unnecessary
days of therapy was longer than necessary treatment
(234 days of therapy); longer than necessary therapy was
attributable to treatment for longer than recommended
durations (121 days of therapy) or failure to discontinue
Figure 1 Overview of Findings Regarding Necessity of
Fluoroquinolone Regimens.
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Characteristic Unnecessary
(n = 70)
Necessary
(n = 157)
P Value
Age in years-median (IQR) 65 (49, 80) 59 (45, 72) 0.045
Males 30 (43) 70 (45) 0.81
Hospitalized in previous 12 months 48 (69) 101 (64) 0.58
Antibiotics in previous 3 months 29 (41) 83 (53) 0.11
FQ antibiotics in previous 3 months 11 (16) 33 (21) 0.35
Long-term care resident 20 (29) 36 (23) 0.38
Comorbidities
Diabetes 23 (33) 53 (34) 0.89
Cancer 9 (13) 30 (19) 0.25
Chronic neurological condition 17 (24) 28 (18) 0.26
Dementia 12 (17) 16 (10) 0.14
Service First Prescribing FQs
Emergency Department 22 (31) 55 (35) 0.60
Medicine 25 (36) 68 (43) 0.28
Surgery 6 (9) 21 (13) 0.38
Family Practice 8 (11) 6 (4) 0.04
Rehabilitation Medicine 9 (13) 3 (2) 0.002
Obstetrics/Gynecology 0 (0) 4 (3) 0.31
Indication
Treatment 68 (97) 150 (96) 0.73
Prophylaxis 2 (3) 7 (4)
Regimen
FQ as monotherapy 46 (66) 51 (32) < 0.001
FQ in combination with other antimicrobials 24 (34) 106 (68)
Syndrome
Urinary 36 (51) 28 (18) < 0.001
Pulmonary 2 (3) 50 (32) < 0.001
Upper respiratory tract 4 (6) 9 (6) 1.000
Bacteremia 3 (4) 7 (4) 1.000
Fever or sepsis syndrome 3 (4) 11 (7) 0.56
Diarrhea 2 (3) 3 (2) 0.65
Intra-abdominal 2 (3) 20 (13) 0.03
Skin and soft tissue 4 (6) 7 (5) 0.74
Non-infectious condition 11 (16) 18 (11) 0.39
Other 3 (4) 4 (3) 0.68
Interquartile range (IQR). Data are number of regimens (percentage of regimen category) unless otherwise indicated. Categorical data were assessed using Pearson Chi-
square test or Fisher’s exact test; Fisher’s exact test was used for categorical data when the expected value for any given cell was less than 10.
Table 2 Reasons for Unnecessary Days of fluoroquinolone therapy
Number of Regimens
(Days of Therapy)
Unnecessary fluoroquinolone regimens (n = 70)
Non-infectious or non-bacterial syndrome 54 (292)
Redundant antimicrobial coverage 10 (58)
Coverage broader than necessary 5 (35)
Inadequate coverage 1 (6)
Part of necessary fluoroquinolone regimen unnecessary (n = 50)
Duration of treatment longer than necessary 23 (121)
Treatment not discontinued when no evidence of infection 16 (113)
Redundant coverage 4 (21)
Inadequate coverage 7 (44)
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days of therapy).
Urinary syndromes, including asymptomatic bacter-
iuria, urinary tract infection, and pyelonephritis,
accounted for 51% of the unnecessary fluoroquinolone
regimens. In addition, urinary syndromes accounted for
36 of the 299 (12%) days of unnecessary therapy that
were prescribed as part of necessary regimens. In total,
urinary syndromes accounted for 210 of the 690 (30%)
unnecessary days of fluoroquinolone therapy.
For necessary fluoroquinolone regimens, we also
assessed whether equally effective alternative agents
could have been used for therapy. Of 157 necessary regi-
mens, 87 (55%) could have been replaced with an alter-
native agent; these regimens accounted for 648 of 1773
(37%) total days of fluoroquinolone therapy. The most
common indications for which alternative agents could
have been used were gastrointestinal infections (22 regi-
mens, 184 days of therapy), pulmonary infections (21
regimens, 159 days of therapy), and urinary tract infec-
tions (21 regimens, 132 days of therapy).
Table 3 shows the adverse events associated with the
120 antibiotic regimens that include unnecessary fluoro-
quinolone therapy (70 unnecessary regimens and 50
necessary regimens that included unnecessary days of
therapy). Gastrointestinal side effects were most fre-
quent adverse events, followed by colonization or infec-
tion with resistant organisms, Clostridium difficile
infection, and Candida infection.
During the study period, 11,304 total days of antibiotic
therapy were administered to inpatients. Fluoroquino-
lones accounted for 1,959 of the total days of antibiotic
therapy (17%). Ciprofloxacin was the most commonly
used fluoroquinolone (1,627 days of therapy); moxifloxa-
cin accounted for the remaining 332 days of therapy.
Assuming that fluoroquinolone therapy during the study
period was representative of usage patterns throughout
the year, the estimated total cost of all of fluoroquino-
lones administered in 2009 was $205,051 ($127,877 for
ciprofloxacin and $77,174 for moxifloxacin). Based on
actual pharmacy acquisition charges, the total costs of
all fluoroquionolones administered in 2009 was $22,281
($11,144 for ciprofloxacin and $11,137 for moxifloxacin).
If a stewardship program had been effective in eliminat-
ing the 31% of fluoroquinolone therapy that was consid-
ered unnecessary, the estimated cost savings for the
hospital based only on pharmacy expenditures during
the year of the study would have been ~$63,566 based
on average wholesale prices or $6,907 in actual phar-
macy acquisition costs.
Discussion
We found that 31% of fluoroquinolone regimens pre-
scribed in our institution during the study period were
unnecessary. These unnecessary regimens accounted for
22% of all days of fluoroquinolone therapy (391 of 1,773
total days of therapy). The most common reason for
unnecessary fluoroquinolone regimens was administra-
tion of antimicrobials for non-infectious or non-bacterial
syndromes. These findings are consistent with previous
studies that evaluated appropriateness of fluoroquino-
lone therapy regimens [8-11]. For example, Lautenbach
et al. [8] found that there was no evidence of infection
in 33% of the fluoroquinolone prescriptions that were
deemed inappropriate in two emergency departments.
A new observation from our study is that nearly half
of all unnecessary days of fluoroquinolone therapy (299
of 690 unnecessary days of therapy) occurred when only
part of a treatment regimen was unnecessary. The most
common reason for part of a regimen being unnecessary
was administration of fluoroquinolones for longer than
necessary durations, either because treatment duration
was longer than is recommended in current guidelines
or because therapy was not discontinued when there
Table 3 Adverse Events Associated with Unnecessary Fluoroquinolone Antimicrobial Therapy
Adverse Event All
Unnecessary Regimens
(n = 70)
*Unnecessary
monotherapy
regimens
(n = 45)
Necessary Regimens
with Unnecessary
Days of Therapy
(n = 50)
GI symptoms 8 (11) 4 (9) 9 (18)
Resistant organism colonization or infection 6 (9) 1 (2) 7 (14)
Clostridium difficile infection 0 0 3 (6)
Candida infection 1 (1) 1 (2) 5 (10)
Allergy 2 (3) 0 0
Renal complications 1 (1) 1 (2) 0
Phlebitis 1 (1) 0 0
Other 1 (1) 0 0
Data are presented as number of regimens (percent). * = unnecessary monotherapy regimens are the subset of all unnecessary fluoroquinolone regimens that included
only a fluoroquinolone. Resistant organism colonization or infection refers to fluoroquinolone-resistant gram-negative bacilli, vancomycin resistant enterococci, or
methicillin-resistant Staphylococcus aureus isolated from a patient with no previous cultures positive for those organisms. Allergy refers to an allergic reaction (e.g.,
rash) possibly attributable to fluoroquinolone therapy. The single adverse event that was listed in the other category was hematologic adverse effect.
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interventions to reduce overuse of fluoroquinolones
should include efforts to ensure that the duration of
therapy is appropriate. Such measures may be clinically
important because increased duration of fluoroquino-
lone therapy has been associated with increased risk of
CDI [16]. Efforts to reduce the length of antimicrobial
regimens have been advocated as a safe and palatable
means to limit overuse of antibiotics [17].
Urinary syndromes were the most common reason for
unnecessary fluoroquinolone therapy (30% of all unne-
cessary days of therapy). Treatment of asymptomatic
bacteriuria accounted for 51% of all unnecessary fluoro-
quinolone regimens, and was particularly common in
elderly patients. It is likely that we underestimated the
actual number of cases of asymptomatic bacteriuria
because documentation of urinary symptoms in the
medical record was sometimes lacking and we required
documentation that urinary symptoms were not present
to classify a case as asymptomatic bacteriuria. Current
guidelines for management of asymptomatic bacteriuria
recommend treatment only for pregnant women or indi-
viduals undergoing invasive urologic procedures [18].
This recommendation is based on randomized trials
that have demonstrated that treatment of asymptomatic
bacteriuria is not beneficial in other patient populations
[18-22]. A recent survey in our hospital demonstrated
that most physicians were unaware of the guidelines for
management of asymptomatic bacteriuria (authors’
unpublished data). To address the overuse of fluoroqui-
nolones in our facility, we have initiated an intervention
that focuses primarily on improving adherence to cur-
rent guidelines for management of asymptomatic bacter-
iuria and other urinary syndromes. The intervention
includes education, audit and feedback regarding appro-
priateness of therapy, and automated electronic remin-
ders regarding appropriate choice and duration of
therapy.
In addition to the evaluation of the necessity of fluor-
oquinolone therapy, we assessed whether equally effec-
tive alternative agents could have been used for therapy.
Of the necessary fluoroquinolone regimens, we found
that 55% could have been replaced with an alternative
agent; these regimens accounted for 37% of the total
days of fluoroquinolone therapy. Therefore, our findings
suggest that a stewardship program that includes both
elimination of unnecessary therapy and formulary sub-
stitution when effective alternatives are available could
eliminate up to 75% of days of fluoroquinolone therapy
without adversely affecting care of patients.
Our study has some limitations. First, the study was
conducted in a single tertiary care institution. Additional
studies are needed in other tertiary care hospitals and in
community hospitals. Second, categorization of therapy
as necessary or unnecessary was based on review of
medical records, and therefore it is possible that some
regimens were misclassified due to inadequate docu-
mentation of the indications for treatment. However, as
noted previously, the reviewers did not classify therapy
as unnecessary in cases where inadequate documenta-
tion was available. Third, we examined fluoroquinolone
use during a single 6-week period in the springtime. It
is possible that fluoroquinolone use may be greater dur-
ing the winter respiratory virus season. Fourth, we did
not include a comparison of the appropriateness of pre-
scribing for physicians at different levels of training.
Finally, for regimens in which fluoroquinolones were
administered in combination with other agents, it is not
possible to determine whether adverse effects were attri-
butable to the fluoroquinolones or to the other agents.
Conclusions
Fluoroquinolones accounted for 17% of all days of anti-
biotic therapy in our institution, and 39% of all days of
fluoroquinolone therapy were unnecessary. The most
common reasons for unnecessary therapy were adminis-
tration of antimicrobials for non-infectious or non-bac-
terial syndromes and administration of antimicrobials
for longer than recommended durations. These results
suggest that interventions that focus on improving
adherence with current guidelines for antimicrobial use
and for duration of therapy could significantly reduce
overuse of fluoroquinolones.
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